Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Expands Black Box With Heart Attack Risk Information

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.

You may also be interested in...



FDA Grants GSK's Advair Broader Use

Top-selling asthma drug cleared for COPD flare-ups.

FDA Grants GSK's Advair Broader Use

Top-selling asthma drug cleared for COPD flare-ups.

Avandia Market Share Stabilizing, GSK CEO Garnier Says

In his last earnings presentation, Garnier says it is unclear whether the type 2 diabetes drug will become a growth driver again.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel